Steven Stice is leading researchers at the University of Georgia’s Regenerative Bioscience Center in a newly funded research consortium designed to hasten the development of advanced cell therapies for a range of chronic diseases, including heart disease and cancer.
With $20 million in funding from the National Science Foundation, the Engineering Research Center for Cell Manufacturing Technologies, dubbed CMaT, will bring together RBC researchers, industry partners, clinicians, engineers, cell biologists and immunologists.
“Partnerships of this nature-that span different universities and sectors-are critical to advancing human health around the world,” said UGA President Jere W. Morehead, “and I want to congratulate Dr. Stice and his team at the University of Georgia for helping to drive this important research center.”
The flow of innovative ideas and techniques from this regional “manufacturing hub” based at the Georgia Institute of Technology could create a pipeline of therapies and lifetime cures for an aging population challenged by escalating chronic diseases.
“We have a richer set of engineering resources to draw on than ever before, due in large part to the incredible talent UGA has been able to attract from across the country and around the world,” said Stice, a Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. “Working alongside seasoned veterans like GRA Eminent Scholar Art Edison in the university’s Complex Carbohydrate Research Center, we can break through manufacturing bottlenecks and bring a new approach in CAR-T cell therapy to treat cancer.”